{"id":"W4397007301","doi":"10.1016/j.esmoop.2024.103220","title":"198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Japanese Society of Medical Oncology; Daewoong Pharmaceutical Company; Chugai Pharmaceutical; Seagen; Radius Health; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Immunotherapy; Cancer; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006331427,0.001404087,0.002497629,0.0005910351,0.0004265275,0.0009103342,0.0008961195,0.0004717316,0.006215059],"category_scores_gemma":[0.0001277392,0.001036583,0.000574681,0.001145046,0.0003716263,0.001341682,0.0002256884,0.001131268,0.0002204338],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003250182,"about_ca_system_score_gemma":0.004885531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003446145,"about_ca_topic_score_gemma":0.0008229856,"domain_scores_codex":[0.9926797,0.0002843837,0.001927245,0.002233918,0.001467307,0.001407451],"domain_scores_gemma":[0.9957716,0.0004171558,0.000680502,0.001829126,0.0006504454,0.0006511973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.6139864,0.003658763,0.003343382,0.002749763,0.01720127,0.003694676,0.03420617,0.001875063,0.002342561,0.0009300765,0.1217705,0.1942413],"study_design_scores_gemma":[0.307555,0.01582085,0.0250018,0.007012761,0.003371124,0.002823804,0.002776964,0.0193033,0.0187287,0.002349418,0.5898689,0.005387405],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9512585,0.002957857,0.009769526,0.01146712,0.003500938,0.01458094,0.0007351111,0.001009474,0.004720488],"genre_scores_gemma":[0.9596414,0.001074049,0.008181576,0.008741322,0.0008756815,0.006509206,0.001242697,0.0006400651,0.01309401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4680984,"threshold_uncertainty_score":0.999871,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04492359654625794,"score_gpt":0.335588798989936,"score_spread":0.2906652024436781,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}